Latest Regulatory News

MTM Critical Metals has locked in a pre-permitted industrial site in Texas, positioning itself to commission its innovative metal recovery plant by year-end 2025 and accelerate U.S. commercial expansion.

DMC Mining Limited has issued its Third Supplementary Prospectus, extending key deadlines for its Public Offer and loan repayment as exploration permits for its Guinean projects remain pending.

White Cliff Minerals has reported further high-grade copper intercepts from its 2025 drilling campaign at the Rae Copper Project in Nunavut, confirming a shallow, open copper system with promising development potential.

Paladin Energy reports a 17% rise in quarterly uranium production and US$61 million in revenue, while recognizing a US$19.9 million inventory impairment. The company maintains strong liquidity and advances key projects in Namibia and Canada.

Patriot Battery Metals has announced a substantial upgrade to its Shaakichiuwaanaan Lithium Project, solidifying its position as the largest lithium pegmatite resource in the Americas and advancing its feasibility study on track for Q3 2025.

West African Resources has commenced mining and crushing at its Kiaka Gold Project in Burkina Faso, maintaining its schedule and budget for first gold production in the third quarter of 2025. The project’s progress signals a significant boost to the company’s annual gold output.

Humm Group reported a solid 10% increase in assets under management to $5.3 billion for 3Q25, maintaining stable margins while advancing a new hybrid loan product and IT platform modernization.

Holista Colltech Limited has responded to an ASX price query regarding recent unusual trading activity, confirming no undisclosed material information exists to explain the surge.

Raptis Group Limited has voluntarily suspended trading on the ASX as it prepares to announce a significant share placement and entitlement offer, signaling a pivotal moment for the company’s capital structure.

PolyNovo has secured Therapeutic Goods Administration clearance for thicker versions of its NovoSorb MTX product, broadening treatment options for complex wounds in Australia.

Ainsworth Game Technology's Independent Board Committee reaffirms its recommendation for shareholders to support the proposed Scheme, responding to recent media commentary from a major shareholder.

Botanix Pharmaceuticals has clarified that recent share price movements are linked to a rumored US executive order on drug pricing, confirming no undisclosed material information. The company reassures investors of compliance with ASX disclosure rules amid market speculation.